Form 4: Veradigm Director Lou Silverman Acquires Over 46,000 Shares Through RSU Grant

Veradigm Inc. Director Lou Silverman has acquired 46,512 shares of common stock through a Restricted Stock Unit grant, increasing his direct beneficial ownership to 56,624 shares.

Summary

• Lou Silverman, a Director of Veradigm Inc. (MDRX), acquired 46,512 shares of common stock.
• The acquisition occurred on June 2, 2025, at a price of $4.3 per share.
• This transaction was an award of Restricted Stock Units (RSUs) granted under the Veradigm, Inc. Amended and Restated 2024 Stock Incentive Plan.
• The RSUs are scheduled to vest 100% on the first anniversary of the grant date, which is June 2, 2026.
• Following this transaction, Mr. Silverman's direct beneficial ownership in Veradigm Inc. stands at 56,624 shares.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is generally viewed positively as it aligns insider interests with shareholders. It does not contain any negative news or unexpected financial performance.

Positives

• The acquisition of shares by a director, even through an RSU grant, can signal alignment of management interests with shareholder interests.
• The grant is part of a formal incentive plan (Amended and Restated 2024 Stock Incentive Plan), indicating structured executive compensation.

Future Outlook

The 46,512 Restricted Stock Units granted to Director Lou Silverman are scheduled to vest 100% on June 2, 2026, which is the first anniversary of the grant date.

Industry Context

Executive compensation through equity awards like Restricted Stock Units (RSUs) is a common practice across various industries, including healthcare information technology, to align the interests of directors and executives with those of shareholders and to incentivize long-term performance. This specific grant to a director of Veradigm Inc. (a healthcare IT company) reflects standard corporate governance practices for executive incentives.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for executive compensation is a widely adopted practice across industries, including healthcare IT, aligning with global benchmarks for incentive-based remuneration.
• The vesting schedule of 100% on the first anniversary of the grant date is a common, though not universal, structure for director equity awards, often seen in companies where short-to-medium term retention and performance alignment are key.
• Without specific details on Veradigm's overall compensation philosophy or peer group compensation data, a direct quantitative comparison of the grant size (46,512 shares at $4.3) to comparable companies like Allscripts (its former parent), Cerner (now Oracle Health), or other healthcare IT providers is not feasible from this document alone.

Corporate Governance

Related Party Transactions

• This document reports an acquisition of shares by a director, which is a related-party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: The use of a stock incentive plan for directors may signal the company's broader commitment to equity-based compensation, which can be a positive for employee retention and motivation.

Next Steps

• The vesting of 46,512 Restricted Stock Units on June 2, 2026.

Key Dates

Keywords

Veradigm, MDRX, SEC Form 4, insider transaction, restricted stock units, RSU, stock award, director compensation, beneficial ownership, Lou Silverman, equity incentive plan